Answers are grounded in this paper and cite their sources.
Background Ovarian cancer is the seventh most common cancer in women and the eighth most common cause of cancer death for women around the world and is commonly known as the “silent killer.” Ovarian cancer is often very quiet until it is advanced, so there is a need for extensive care and support from nurses, in addition to early detection and prompt therapeutic interventions, to enhance patient outcomes and quality of life. Purpose The purpose of this study was to explore the anti-cancer effect of geniposide on ovarian cancer and to gain insight into the mechanism of action of geniposide in the inhibition of cell proliferation and the induction of apoptosis in SKOV3 ovarian cancer cells using in vitro and in silico methods. Methods Cell viability of SKOV3 ovarian cancer cells was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after treatment with geniposide. The apoptotic changes in the untreated and geniposide-treated cells were analyzed by 4’,6-diamidino-2-phenylindole (DAPI) staining and dual acridine orange/ethidium bromide staining. To investigate the underlying molecular mechanism of apoptosis, the anti-apoptotic protein B-cell lymphoma 2 (BCL-2) was chosen as a target, and molecular docking studies were carried out to assess the interaction of geniposide with BCL-2. Results The treatment with geniposide markedly reduced the proliferation of SKOV3 cells in a dose-dependent way. Moreover, geniposide significantly increased apoptotic cell death, as observed in the DAPI and dual staining analysis. The in silico studies revealed that geniposide showed a good interaction with BCL-2, with a binding affinity of −6.3 kcal/mol and a root mean square deviation of 2.581 Å, indicating that geniposide might inhibit BCL-2-mediated anti-apoptotic signaling. Conclusion In conclusion, the results suggest that geniposide possesses potent anti-cancer effects on SKOV3 ovarian cancer cells by inhibiting cell viability and inducing apoptosis, possibly via regulating BCL-2-mediated signaling pathways. These results suggest that geniposide may serve as a promising candidate for future ovarian cancer therapy. From a nursing care perspective, the development of effective and less toxic therapeutic agents such as geniposide may contribute to improved patient management, reduced treatment-related complications, enhanced quality of life, and better overall clinical outcomes in women with ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: